NCT03113617View on ClinicalTrials.gov

68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 10, 2017

Primary Completion Date

December 19, 2021

Study Completion Date

December 19, 2021

Conditions

Stage II Prostate AdenocarcinomaStage III Prostate AdenocarcinomaStage IV Prostate Adenocarcinoma

Interventions

PROCEDURE

Computed Tomography

Undergo PET/CT

DRUG

Gallium Ga 68-labeled GRPR Antagonist BAY86-7548

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo PET/CT

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors

lead

Andrei Iagaru

OTHER

NCT03113617 - 68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer | Biotech Hunter | Biotech Hunter